These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19016571)

  • 1. Mild to moderate Crohn's disease: an evidence-based treatment algorithm.
    Wong K; Bressler B
    Drugs; 2008; 68(17):2419-25. PubMed ID: 19016571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ; Feagan BG; Lichtenstein GR
    Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
    Panaccione R; Steinhart AH; Bressler B; Khanna R; Marshall JK; Targownik L; Afif W; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C; Bernstein CN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1680-1713. PubMed ID: 30853616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.
    Lichtenstein GR; Hanauer SB; Kane SV; Present DH
    Inflamm Bowel Dis; 2004 Jul; 10 Suppl 2():S2-10. PubMed ID: 15475770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild-to-moderate active luminal Crohn's disease.
    Michetti P; Juillerat P; Mottet C; Pittet V; Gonvers JJ; Vader JP; Froehlich F; Felley C
    Digestion; 2007; 76(2):92-8. PubMed ID: 18239399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: medical treatment of mild to moderately active Crohn's disease.
    Löfberg R
    Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():18-22. PubMed ID: 12786608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild Crohn's Disease: Definition and Management.
    Claytor J; Kumar P; Ananthakrishnan AN; Colombel JF; Agrawal M; Ungaro RC
    Curr Gastroenterol Rep; 2023 Mar; 25(3):45-51. PubMed ID: 36753033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of Crohn's disease.
    Cottone M; Renna S; Orlando A; Mocciaro F
    Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: maintenance treatment of Crohn's disease.
    Biancone L; Tosti C; Fina D; Fantini M; De Nigris F; Geremia A; Pallone F
    Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():31-7. PubMed ID: 12786610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical therapy of inflammatory bowel diseases: Crohn's disease].
    Lakatos L; Lakatos PL
    Orv Hetil; 2007 Jun; 148(24):1107-14. PubMed ID: 17561480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Crohn's disease].
    Beglinger Ch
    Ther Umsch; 2003 Mar; 60(3):159-63. PubMed ID: 12693319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
    Naseer M; Poola S; Ali S; Samiullah S; Tahan V
    Curr Clin Pharmacol; 2020; 15(3):216-233. PubMed ID: 32164516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the limitations of corticosteroid therapy in Crohn's disease.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1515-25. PubMed ID: 11563990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.